Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes

Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment...

Full description

Bibliographic Details
Main Authors: Morten Hindsø, Christoffer Martinussen, Maria Saur Svane, Simon Veedfald, Birthe Gade-Rasmussen, Torben Hansen, Sten Madsbad
Format: Article
Language:English
Published: SMC MEDIA SRL 2021-03-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
neonatal diabetes
kcnj11
sulfonylurea
glp-1
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/2352
Description
Summary:Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months’ follow-up.
ISSN:2284-2594

Similar Items